BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Apr 29, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

AeroVanc: Phase II started

Savara began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate twice-daily 32 and 64 mg AeroVanc for 28 days in about 80 patients. Patients with co-infected with Pseudomonas aeruginosa will undergo a 28-day run-in, in which patients will...

Read the full 175 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >